Hans Friedrich Stabenau1, Changyu Shen2, Larisa G Tereshchenko3, Jonathan W Waks4. 1. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. 2. Smith Center for Outcomes Research in Cardiology Beth Israel Deaconess Medical Center Harvard Medical School, Boston, Massachusetts. 3. Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon. 4. Harvard-Thorndike Electrophysiology Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. Electronic address: jwaks@bidmc.harvard.edu.
Abstract
BACKGROUND: Electrocardiographic (ECG) markers of antiarrhythmic drug (AAD) activity could be used to optimize efficacy and minimize toxicity. Vectorcardiographic global electrical heterogeneity (GEH) is associated with ventricular arrhythmias and sudden death, but it is unclear how GEH measurements change in response to AADs. OBJECTIVE: The purpose of this study was to characterize acute effects of AADs on GEH measurements. METHODS: We analyzed double-blind placebo-controlled trial data from healthy volunteers given 1 dose ofplacebo, dofetilide, quinidine, ranolazine, or verapamil on subsequent visits. Serial ECGs and plasma drug concentrations were collected. Vectorcardiographic GEH parameters (spatial ventricular gradient [SVG], spatial QRST angle, sum absolute QRST integral, and SVG-QRS peak angle) were measured. Placebo-corrected change from baseline was regressed on drug concentration stratified by sex using linear mixed effects models. RESULTS: Among 22 persons (11 (50%) male median age 27 ± 5 years), 5232 ECGs were analyzed. Dofetilide and quinidine were associated with significant changes in more GEH parameters (5) compared with verapamil (2) and ranolazine (1). The most notable change occurred in SVG azimuth, with largest changes (degrees per unit normalized drug concentration) in dofetilide (6.1; 95% confidence interval [CI] 4.2-8.0) and quinidine (9.4; 95% CI 6.7-12.0), and smaller effects in verapamil (4.4; 95% CI 2.9-5.9) and ranolazine (5.4; 95% CI 3.5-7.3). AAD-induced GEH changes significantly differed in men and women. CONCLUSION: AADs change GEH measurements. These changes, which differ by sex, are likely driven by alterations in ion channel function and dispersion of depolarization or repolarization. GEH measurement may allow early assessment of favorable or adverse AAD effects.
RCT Entities:
BACKGROUND: Electrocardiographic (ECG) markers of antiarrhythmic drug (AAD) activity could be used to optimize efficacy and minimize toxicity. Vectorcardiographic global electrical heterogeneity (GEH) is associated with ventricular arrhythmias and sudden death, but it is unclear how GEH measurements change in response to AADs. OBJECTIVE: The purpose of this study was to characterize acute effects of AADs on GEH measurements. METHODS: We analyzed double-blind placebo-controlled trial data from healthy volunteers given 1 dose of placebo, dofetilide, quinidine, ranolazine, or verapamil on subsequent visits. Serial ECGs and plasma drug concentrations were collected. Vectorcardiographic GEH parameters (spatial ventricular gradient [SVG], spatial QRST angle, sum absolute QRST integral, and SVG-QRS peak angle) were measured. Placebo-corrected change from baseline was regressed on drug concentration stratified by sex using linear mixed effects models. RESULTS: Among 22 persons (11 (50%) male median age 27 ± 5 years), 5232 ECGs were analyzed. Dofetilide and quinidine were associated with significant changes in more GEH parameters (5) compared with verapamil (2) and ranolazine (1). The most notable change occurred in SVG azimuth, with largest changes (degrees per unit normalized drug concentration) in dofetilide (6.1; 95% confidence interval [CI] 4.2-8.0) and quinidine (9.4; 95% CI 6.7-12.0), and smaller effects in verapamil (4.4; 95% CI 2.9-5.9) and ranolazine (5.4; 95% CI 3.5-7.3). AAD-induced GEH changes significantly differed in men and women. CONCLUSION: AADs change GEH measurements. These changes, which differ by sex, are likely driven by alterations in ion channel function and dispersion of depolarization or repolarization. GEH measurement may allow early assessment of favorable or adverse AAD effects.
Authors: A L Goldberger; L A Amaral; L Glass; J M Hausdorff; P C Ivanov; R G Mark; J E Mietus; G B Moody; C K Peng; H E Stanley Journal: Circulation Date: 2000-06-13 Impact factor: 29.690
Authors: Roderick W C Scherptong; Ivo R Henkens; Sum Che Man; Saskia Le Cessie; Hubert W Vliegen; Harmen H M Draisma; Arie C Maan; Martin J Schalij; Cees A Swenne Journal: J Electrocardiol Date: 2008-09-25 Impact factor: 1.438
Authors: Erick Andres Perez-Alday; Yin Li-Pershing; Aron Bender; Christopher Hamilton; Jason A Thomas; Kyle Johnson; Tiffany L Lee; Ryan Gonzales; Aaron Li; Kelley Newton; Larisa G Tereshchenko Journal: Comput Biol Med Date: 2018-11-17 Impact factor: 4.589
Authors: L Johannesen; J Vicente; J W Mason; C Sanabria; K Waite-Labott; M Hong; P Guo; J Lin; J S Sørensen; L Galeotti; J Florian; M Ugander; N Stockbridge; D G Strauss Journal: Clin Pharmacol Ther Date: 2014-07-23 Impact factor: 6.875
Authors: Jonathan W Waks; Colleen M Sitlani; Elsayed Z Soliman; Muammar Kabir; Elyar Ghafoori; Mary L Biggs; Charles A Henrikson; Nona Sotoodehnia; Tor Biering-Sørensen; Sunil K Agarwal; David S Siscovick; Wendy S Post; Scott D Solomon; Alfred E Buxton; Mark E Josephson; Larisa G Tereshchenko Journal: Circulation Date: 2016-04-14 Impact factor: 29.690
Authors: Stefan H Hohnloser; Harry J G M Crijns; Martin van Eickels; Christophe Gaudin; Richard L Page; Christian Torp-Pedersen; Stuart J Connolly Journal: N Engl J Med Date: 2009-02-12 Impact factor: 91.245
Authors: Jose Vicente; Lars Johannesen; Jay W Mason; William J Crumb; Esther Pueyo; Norman Stockbridge; David G Strauss Journal: J Am Heart Assoc Date: 2015-04-13 Impact factor: 5.501
Authors: Kazi T Haq; Katherine J Lutz; Kyle K Peters; Natalie E Craig; Evan Mitchell; Anish K Desai; Nathan W L Stencel; Elsayed Z Soliman; João A C Lima; Larisa G Tereshchenko Journal: J Electrocardiol Date: 2021-10-02 Impact factor: 1.438
Authors: James D Pollard; Kazi T Haq; Katherine J Lutz; Nichole M Rogovoy; Kevin A Paternostro; Elsayed Z Soliman; Joseph Maher; Joao Ac Lima; Solomon Musani; Larisa G Tereshchenko Journal: BMJ Open Date: 2021-01-31 Impact factor: 2.692
Authors: Hans F Stabenau; Changyu Shen; Peter Zimetbaum; Alfred E Buxton; Larisa G Tereshchenko; Jonathan W Waks Journal: Heart Rhythm Date: 2020-08-08 Impact factor: 6.343
Authors: Stacey J Howell; David German; Aron Bender; Francis Phan; Srini V Mukundan; Erick A Perez-Alday; Nichole M Rogovoy; Kazi T Haq; Katherine Yang; Ashley Wirth; Kelly Jensen; Larisa G Tereshchenko Journal: Cardiovasc Digit Health J Date: 2020-10-22